Company Overview - International Flavors & Fragrances Inc. (IFF) has a market capitalization of $17.9 billion and operates in the food, beverage, health, biosciences, and fragrance industries through four main segments: Taste, Food Ingredients, Health & Biosciences, and Scent [1] - The company develops flavor solutions for various products, including beverages, dairy, snacks, bakery items, and savory foods, as well as specialty ingredients and natural preservatives [2] Stock Performance - IFF shares have decreased by 17.1% from their 52-week high of $84.45, but have increased by 10.7% over the past three months, outperforming the S&P 500 Index, which declined by 2.3% during the same period [3] - Year-to-date, IFF stock is up 3.9%, while the S&P 500 Index has dropped by 2.5%. However, over the past 52 weeks, IFF shares have declined nearly 12%, lagging behind the S&P 500 Index's return of 19.2% [4] Financial Performance - Following the Q4 2025 results released on February 11, IFF shares rose by 5.9%. In this quarter, adjusted operating EBITDA increased by 7% to $437 million, and adjusted EPS reached $0.80, reflecting productivity gains and cost discipline [5] - The company provided guidance for 2026, projecting sales between $10.5 billion and $10.8 billion, and adjusted operating EBITDA between $2.05 billion and $2.15 billion, alongside strategic actions such as initiating a sale process for the Food Ingredients segment to enhance portfolio focus and financial flexibility [5] Competitive Position - IFF's stock performance has been weaker compared to its rival, Linde plc (LIN), which has returned 15% year-to-date and 8.7% over the past 52 weeks [6]

Summary of International Flavors & Fragrances (IFF) Conference Call Company Overview - **Company**: International Flavors & Fragrances (NYSE:IFF) - **Date**: February 19, 2026 - **Key Speakers**: CFO Michael DeVeau, Yuvraj Arora (Taste Division), Leticia Gonçalves (Health & Biosciences), Ana Paula Mendonça (Scent Division) Core Industry Insights - **Industry**: Flavors and Fragrances - **Market Dynamics**: The industry is characterized by high barriers to entry, steady growth, and good margins. IFF represents 1%-5% of product costs but accounts for 50% of consumer purchasing decisions due to taste and smell [4][5][6]. Financial Performance - **Sales Growth**: IFF achieved $2.5 billion in net sales in 2025 with a 4% organic top-line growth and 10% EBITDA growth [19][28]. - **EBITDA Margins**: The Taste division reported a 19% EBITDA margin, while the Scent division achieved a 21% EBITDA margin [19][41]. - **Capital Structure**: IFF divested 11 businesses, generating $6 billion in proceeds, which improved their capital structure from 4.5 times net cash and credit-adjusted EBITDA in 2023 to 2.6 times [9][13]. Strategic Initiatives - **Portfolio Optimization**: Focus on divesting lower-margin businesses and reinvesting in higher-margin opportunities. The average gross margin of divested businesses was 29%, compared to a projected 36% for the remaining portfolio by 2025 [12][13]. - **Capital Expenditure**: Planned CapEx spending is projected to increase from 4% in 2024 to around 6% in 2026, focusing on capacity expansion and digital transformation [10][11]. - **Share Buyback Program**: IFF authorized a $500 million share buyback program for the first time in several years, indicating confidence in the intrinsic value of the business [14]. Division-Specific Highlights Taste Division - **Market Size**: The flavors market is estimated at $16-$17 billion, growing at 3%-4% annually [18]. - **Competitive Position**: IFF holds leading positions in key markets like India, Indonesia, and the U.S. and has a unique go-to-market model called Taste One for smaller customers [19][20]. - **Innovation Focus**: Emphasis on AI for flavor development and concept creation, reducing innovation timelines for customers [20][21]. Health & Biosciences Division - **Market Size**: The health and biosciences market is valued between $12 billion and $20 billion, growing at 2.5% annually [31]. - **Product Reach**: IFF's probiotics are in one out of three probiotic supplements and yogurts globally, indicating strong market penetration [30]. - **R&D Investment**: IFF invests $220 million annually in R&D, representing 9% of turnover, with 34% of revenue coming from new product launches in the last five years [35]. Scent Division - **Sales Performance**: The Scent division achieved $2.5 billion in sales with 22 consecutive quarters of growth [41][56]. - **Innovation in Fragrance**: IFF has pioneered fragrance encapsulation and is focusing on sustainable solutions and personalization trends driven by younger consumers [44][48]. - **Market Trends**: The division is adapting to clean label demands and the growing role of scent in health and well-being [48][49]. Conclusion - **Growth Strategy**: IFF aims for mid-single-digit top-line growth and high-single-digit EBITDA growth, focusing on innovation, portfolio optimization, and strategic market penetration [28][40][56]. - **Long-term Vision**: The company is committed to leveraging its diversified business model and strong R&D capabilities to drive sustainable growth and value creation [4][28].

Core Viewpoint - International Flavors & Fragrances Inc. (IFF) is facing challenges with a projected decline in earnings per share (EPS) for fiscal Q4 2025, despite having exceeded earnings expectations in the past four quarters [2][6]. Financial Performance - IFF is expected to report an EPS of $0.84 for fiscal Q4 2025, a 13.4% decline from $0.97 in the same quarter last year [2]. - For fiscal 2025, analysts forecast an EPS of $4.28, slightly down from $4.31 in fiscal 2024, but anticipate a growth of 6.1% year-over-year to $4.54 in fiscal 2026 [3]. Stock Performance - Over the past 52 weeks, IFF's shares have decreased by 15.9%, underperforming the S&P 500 Index's return of 16.7% and the State Street Materials Select Sector SPDR ETF's gains of 12.5% [4]. - The stock's decline is attributed to concerns over slow turnaround progress and operational challenges, including lower demand and high raw material costs [5]. Revenue Insights - In Q3 2025, IFF reported revenue of approximately $2.7 billion, reflecting an 8% decrease from the prior-year quarter [6]. Analyst Sentiment - The consensus view among analysts is cautiously optimistic, with a "Moderate Buy" rating overall. Out of 20 analysts, 12 recommend a "Strong Buy," 2 suggest a "Moderate Buy," and 6 advise a "Hold" [7]. - The average analyst price target for IFF is $81.02, indicating an upside potential of 14.4% [7].

Financial Data and Key Metrics Changes - The company has revised its annual sales guidance down to the lower end of the range, now expecting growth around 1% due to macroeconomic pressures and high comparisons from the previous year [10][12][13] - Cash flow guidance remains at $500 million, with CapEx around 6% of sales, despite some fluctuations in inventory and demand [58][59] Business Line Data and Key Metrics Changes - The Health and Beauty (H and B) business has faced challenges, particularly in the probiotics segment, which has seen low single-digit CAGR over the past few years [16][18] - The Fragrance Ingredients business is expected to recover by 2026, despite current short-term pressures and competition from low-cost providers [26][27] - The Taste segment has shown broad-based growth, particularly in beverages and dairy, driven by new wins and innovation [38] Market Data and Key Metrics Changes - North America has experienced declines across all divisions, while Europe and Latin America are performing better [13] - The company is focusing on expanding its presence in emerging markets, particularly in the Health and Beauty sector [63] Company Strategy and Development Direction - The company is prioritizing a return to core values and disciplined operations, focusing on innovation and R&D to enhance customer service [3][5] - There is a strategic shift towards specialty products to mitigate competition from low-cost providers, particularly in the Fragrance Ingredients segment [30][31] - The company plans to increase capital expenditures to enhance enzyme capacity and overall business performance [34] Management's Comments on Operating Environment and Future Outlook - Management acknowledges macroeconomic uncertainties impacting performance but remains optimistic about long-term growth opportunities, particularly in innovation and customer engagement [11][21] - The company expects improvements in the Health business by 2026 as new R&D investments begin to yield results [22] Other Important Information - The company has made significant investments in R&D, with a planned $100 million investment in 2025 to enhance its product pipeline [20] - The leadership team has seen changes, with a mix of internal and external talent, which management believes strengthens the company's capabilities [90][92] Q&A Session Summary Question: What has changed to take your annual sales guidance down to the lower end of the range? - The company has revised its guidance due to macroeconomic pressures and high comparisons from the previous year, now expecting growth around 1% [10][12] Question: Can you provide an overview of the Health business and its challenges? - The Health business, primarily focused on probiotics, has faced performance challenges, particularly in China and North America, but management is optimistic about future improvements [16][18][19] Question: What is the outlook for the Fragrance Ingredients business? - Management expects a recovery in the Fragrance Ingredients business by 2026, despite current pressures from low-cost competition [26][27] Question: How is the Taste segment performing? - The Taste segment has shown strong growth, particularly in beverages and dairy, driven by new wins and innovation [38] Question: What are the company's strategic priorities moving forward? - The company is focused on returning to core values, enhancing innovation, and increasing capital expenditures to improve overall business performance [3][5][34]